SG151316A1 - Methods for inducing autolysis in infectious bacteria - Google Patents

Methods for inducing autolysis in infectious bacteria

Info

Publication number
SG151316A1
SG151316A1 SG200902143-7A SG2009021437A SG151316A1 SG 151316 A1 SG151316 A1 SG 151316A1 SG 2009021437 A SG2009021437 A SG 2009021437A SG 151316 A1 SG151316 A1 SG 151316A1
Authority
SG
Singapore
Prior art keywords
infection
methods
treatment
autolysis
infectious bacteria
Prior art date
Application number
SG200902143-7A
Other languages
English (en)
Inventor
Keith Alan Charlton
Andrew Justin Radcliffe Porter
Ian Broadbent
Original Assignee
Haptogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haptogen Ltd filed Critical Haptogen Ltd
Publication of SG151316A1 publication Critical patent/SG151316A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG200902143-7A 2004-03-27 2005-03-24 Methods for inducing autolysis in infectious bacteria SG151316A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0407008.2A GB0407008D0 (en) 2004-03-27 2004-03-27 Methods for inducing rapid cell death (autolysis) in infectious bacteria

Publications (1)

Publication Number Publication Date
SG151316A1 true SG151316A1 (en) 2009-04-30

Family

ID=32188889

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200902143-7A SG151316A1 (en) 2004-03-27 2005-03-24 Methods for inducing autolysis in infectious bacteria

Country Status (15)

Country Link
US (3) US20070218058A1 (xx)
EP (2) EP1730197B1 (xx)
JP (2) JP5167466B2 (xx)
KR (2) KR20130001741A (xx)
CN (1) CN1934134B (xx)
AT (1) ATE548390T1 (xx)
AU (1) AU2005227666B2 (xx)
CA (1) CA2558435A1 (xx)
DK (1) DK1730197T3 (xx)
ES (1) ES2381374T3 (xx)
GB (1) GB0407008D0 (xx)
HK (1) HK1099316A1 (xx)
NO (1) NO20063871L (xx)
SG (1) SG151316A1 (xx)
WO (1) WO2005094883A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110124375A (ko) * 2002-08-13 2011-11-16 햅토젠 리미티드 항-락톤 또는 락톤 유도된 시그널 분자 항체를 이용한 감염성 세균 질환의 치료 방법
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
JP5170403B2 (ja) * 2008-03-14 2013-03-27 国立大学法人 筑波大学 細菌の増殖を制御する化合物及びその応用
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
EP3126333B1 (en) * 2014-04-03 2018-08-01 Helmholtz-Zentrum für Infektionsforschung GmbH Pqsr modulators
CN108513984B (zh) * 2018-04-14 2020-12-29 华南农业大学 Ahl分子作为化学农药杀菌增效剂在黄单胞杆菌引起的黑腐病防治中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6395282B1 (en) * 1998-04-16 2002-05-28 University Of Rochester Immunogenic conjugates of Gram-negative bacterial autoinducer molecules
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
US6309651B1 (en) 1998-11-25 2001-10-30 Mcw Research Foundation Method of and compositions for immunization with the pseudomonas V antigen
GB9924195D0 (en) 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
GB0007588D0 (en) 2000-03-30 2000-05-17 Univ Nottingham N-Acyl homoserine lactones
US6703513B1 (en) * 2000-06-02 2004-03-09 K-Quay Enterprises Llc Production and use of derivatized homoserine lactones
KR20110124375A (ko) * 2002-08-13 2011-11-16 햅토젠 리미티드 항-락톤 또는 락톤 유도된 시그널 분자 항체를 이용한 감염성 세균 질환의 치료 방법
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria

Also Published As

Publication number Publication date
JP2007530649A (ja) 2007-11-01
US20110027280A1 (en) 2011-02-03
CN1934134A (zh) 2007-03-21
EP2261260A2 (en) 2010-12-15
ES2381374T3 (es) 2012-05-25
HK1099316A1 (en) 2007-08-10
ATE548390T1 (de) 2012-03-15
US20070218058A1 (en) 2007-09-20
US20130011400A1 (en) 2013-01-10
EP1730197B1 (en) 2012-03-07
JP5167466B2 (ja) 2013-03-21
CN1934134B (zh) 2012-01-11
AU2005227666B2 (en) 2011-09-01
CA2558435A1 (en) 2005-10-13
JP2013040191A (ja) 2013-02-28
KR20070050865A (ko) 2007-05-16
GB0407008D0 (en) 2004-04-28
WO2005094883A3 (en) 2006-01-12
KR20130001741A (ko) 2013-01-04
AU2005227666A1 (en) 2005-10-13
EP1730197A2 (en) 2006-12-13
EP2261260A3 (en) 2011-01-05
DK1730197T3 (da) 2012-06-25
NO20063871L (no) 2006-08-30
WO2005094883A2 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
Barnabé et al. Efficacy of sodium hypochlorite and coconut soap used as disinfecting agents in the reduction of denture stomatitis, Streptococcus mutans and Candida albicans
HK1099316A1 (en) Methods for inducing autolysis in infectious bacteria
Lee Perspectives towards antibiotic resistance: from molecules to population
Sassone et al. The influence of organic load on the antimicrobial activity of different concentrations of NaOCl and chlorhexidine in vitro
US10244758B2 (en) Compositions comprising a germinant and an antimicrobial agent
Arnold et al. Bacterial biofilms and periprosthetic infections
BR0209057A (pt) Composições herbicidas contendo benzoilciclohexanodionas e protetores
Azman et al. Actinobacteria—a promising natural source of anti-biofilm agents
Khokhar et al. Viricidal treatments for prevention of coronavirus infection
Gupta et al. Ozone gas effectively kills laboratory strains of Trichophyton rubrum and Trichophyton mentagrophytes using an in vitro test system
Pérez de la Lastra et al. Antimicrobial resistance in the COVID-19 landscape: is there an opportunity for anti-infective antibodies and antimicrobial peptides?
Hugar et al. An in vitro comparative evaluation of efficacy of disinfecting ability of garlic oil, neem oil, clove oil, and tulsi oil with autoclaving on endodontic K files tested against Enterococcus faecalis
Dauvergne et al. Brass alloys: Copper-bottomed solutions against hospital-acquired infections?
Lin et al. Application progress of nano silver dressing in the treatment of diabetic foot
EP1639971A4 (en) COMPOSITIONS FOR SKIN PROTECTION
Vadakkan et al. A review of chemical signaling pathways in the quorum sensing circuit of Pseudomonas aeruginosa
CN101491245B (zh) 一种含林蛙抗菌肽的消毒制剂及其制备方法和应用
CN103907598A (zh) 一种氯消毒剂泡腾片
Trizna et al. Improving the efficacy of antimicrobials against biofilm-embedded bacteria using bovine hyaluronidase azoximer (Longidaza®)
Melvin et al. Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms
Wietzikoski Lovato et al. High frequency equipment promotes antibacterial effects dependent on intensity and exposure time
Sada et al. Necrotizing fasciitis and myonecrosis “synergistic necrotizing cellulitis” caused by Bacillus cereus
CN101077362A (zh) 植物型皮肤黏膜消毒剂
CN102754666A (zh) 医疗机构物体表面草本消毒剂
Rodrigues Hoffmann et al. The nature and functions of vertebrate skin microbiota